BIOMAT Database Logo BIOMAT Database Logo

Reversal of adriamycin resistance by recombinant alpha-interferon in multidrug-resistant human colon carcinoma LoVo-doxorubicin cells. 1991

S Scala, and R Pacelli, and R V Iaffaioli, and N Normanno, and S Pepe, and G Frasci, and G Genua, and T Tsuruo, and P Tagliaferri, and A R Bianco
Cattedra di Oncologia Medica, II Facoltà di Medicina, Università di Napoli, Naples, Italy.

Reversal of the drug resistance phenotype by the use of agents which induce cell differentiation offers an experimental approach to the study of chemoresistance. In numerous in vitro models, alpha-interferon (alpha-IFN) has been shown to induce phenotypical changes and to modulate the growth of cancer cells. The aim of the present study was to define the effect of alpha-IFN on the Adriamycin sensitivity of the human colon adenocarcinoma cell line, LoVo, and its Adriamycin-resistant variant, LoVo/DX. Pretreatment of LoVo/DX cells with 500 units/ml of alpha-IFN increased sensitivity to low doses of Adriamycin. Similar treatment conditions did not change the sensitivity of the parental cell line. Following treatment of the LoVo/DX cells with alpha-IFN plus 100 ng/ml Adriamycin for 1 h, 30% of the cells survived compared to 100% of untreated cells. This effect was not related to changes in cell cycle kinetics induced by alpha-IFN treatment and did not result from variations in the expression of P-glycoprotein at the cell surface, as assessed by flow cytometric analysis using monoclonal antibody MRK16. Adriamycin accumulation was increased by alpha-IFN as assessed by spectrofluorometric analysis. Thus, the data suggest that in LoVo/DX cells, alpha-IFN increased Adriamycin cytotoxicity through modulation of the multidrug resistance phenotype.

UI MeSH Term Description Entries
D007370 Interferon Type I Interferon secreted by leukocytes, fibroblasts, or lymphoblasts in response to viruses or interferon inducers other than mitogens, antigens, or allo-antigens. They include alpha- and beta-interferons (INTERFERON-ALPHA and INTERFERON-BETA). Interferons Type I,Type I Interferon,Type I Interferons,Interferon, Type I,Interferons, Type I
D008562 Membrane Glycoproteins Glycoproteins found on the membrane or surface of cells. Cell Surface Glycoproteins,Surface Glycoproteins,Cell Surface Glycoprotein,Membrane Glycoprotein,Surface Glycoprotein,Glycoprotein, Cell Surface,Glycoprotein, Membrane,Glycoprotein, Surface,Glycoproteins, Cell Surface,Glycoproteins, Membrane,Glycoproteins, Surface,Surface Glycoprotein, Cell,Surface Glycoproteins, Cell
D010750 Phosphoproteins Phosphoprotein
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D002453 Cell Cycle The complex series of phenomena, occurring between the end of one CELL DIVISION and the end of the next, by which cellular material is duplicated and then divided between two daughter cells. The cell cycle includes INTERPHASE, which includes G0 PHASE; G1 PHASE; S PHASE; and G2 PHASE, and CELL DIVISION PHASE. Cell Division Cycle,Cell Cycles,Cell Division Cycles,Cycle, Cell,Cycle, Cell Division,Cycles, Cell,Cycles, Cell Division,Division Cycle, Cell,Division Cycles, Cell
D002455 Cell Division The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION. M Phase,Cell Division Phase,Cell Divisions,Division Phase, Cell,Division, Cell,Divisions, Cell,M Phases,Phase, Cell Division,Phase, M,Phases, M
D003110 Colonic Neoplasms Tumors or cancer of the COLON. Cancer of Colon,Colon Adenocarcinoma,Colon Cancer,Cancer of the Colon,Colon Neoplasms,Colonic Cancer,Neoplasms, Colonic,Adenocarcinoma, Colon,Adenocarcinomas, Colon,Cancer, Colon,Cancer, Colonic,Cancers, Colon,Cancers, Colonic,Colon Adenocarcinomas,Colon Cancers,Colon Neoplasm,Colonic Cancers,Colonic Neoplasm,Neoplasm, Colon,Neoplasm, Colonic,Neoplasms, Colon
D004317 Doxorubicin Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN. Adriamycin,Adriablastin,Adriablastine,Adriblastin,Adriblastina,Adriblastine,Adrimedac,DOXO-cell,Doxolem,Doxorubicin Hexal,Doxorubicin Hydrochloride,Doxorubicin NC,Doxorubicina Ferrer Farm,Doxorubicina Funk,Doxorubicina Tedec,Doxorubicine Baxter,Doxotec,Farmiblastina,Myocet,Onkodox,Ribodoxo,Rubex,Urokit Doxo-cell,DOXO cell,Hydrochloride, Doxorubicin,Urokit Doxo cell
D004351 Drug Resistance Diminished or failed response of an organism, disease or tissue to the intended effectiveness of a chemical or drug. It should be differentiated from DRUG TOLERANCE which is the progressive diminution of the susceptibility of a human or animal to the effects of a drug, as a result of continued administration. Resistance, Drug
D004354 Drug Screening Assays, Antitumor Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals. Anticancer Drug Sensitivity Tests,Antitumor Drug Screens,Cancer Drug Tests,Drug Screening Tests, Tumor-Specific,Dye Exclusion Assays, Antitumor,Anti-Cancer Drug Screens,Antitumor Drug Screening Assays,Tumor-Specific Drug Screening Tests,Anti Cancer Drug Screens,Anti-Cancer Drug Screen,Antitumor Drug Screen,Cancer Drug Test,Drug Screen, Anti-Cancer,Drug Screen, Antitumor,Drug Screening Tests, Tumor Specific,Drug Screens, Anti-Cancer,Drug Screens, Antitumor,Drug Test, Cancer,Drug Tests, Cancer,Screen, Anti-Cancer Drug,Screen, Antitumor Drug,Screens, Anti-Cancer Drug,Screens, Antitumor Drug,Test, Cancer Drug,Tests, Cancer Drug,Tumor Specific Drug Screening Tests

Related Publications

S Scala, and R Pacelli, and R V Iaffaioli, and N Normanno, and S Pepe, and G Frasci, and G Genua, and T Tsuruo, and P Tagliaferri, and A R Bianco
Reversal of doxorubicin resistance by the amiloride analogue EIPA in multidrug resistant human colon carcinoma cells.
March 1996, Cell biochemistry and function,
S Scala, and R Pacelli, and R V Iaffaioli, and N Normanno, and S Pepe, and G Frasci, and G Genua, and T Tsuruo, and P Tagliaferri, and A R Bianco
Glucose metabolism in adriamycin-sensitive and -resistant LoVo human colon carcinoma cells.
January 1993, Oncology research,
S Scala, and R Pacelli, and R V Iaffaioli, and N Normanno, and S Pepe, and G Frasci, and G Genua, and T Tsuruo, and P Tagliaferri, and A R Bianco
Reversal of multidrug resistance by icaritin in doxorubicin-resistant human osteosarcoma cells.
January 2018, Chinese journal of natural medicines,
S Scala, and R Pacelli, and R V Iaffaioli, and N Normanno, and S Pepe, and G Frasci, and G Genua, and T Tsuruo, and P Tagliaferri, and A R Bianco
Reversal of 5-flouroucial resistance by adenovirus-mediated transfer of wild-type p53 gene in multidrug-resistant human colon carcinoma LoVo/5-FU cells.
July 2004, World journal of gastroenterology,
S Scala, and R Pacelli, and R V Iaffaioli, and N Normanno, and S Pepe, and G Frasci, and G Genua, and T Tsuruo, and P Tagliaferri, and A R Bianco
Further characterization of two distinct adriamycin-resistant sublines from LoVo human colon carcinoma cells.
January 1992, Anticancer research,
S Scala, and R Pacelli, and R V Iaffaioli, and N Normanno, and S Pepe, and G Frasci, and G Genua, and T Tsuruo, and P Tagliaferri, and A R Bianco
Magnesium homeostasis in colon carcinoma LoVo cells sensitive or resistant to doxorubicin.
November 2015, Scientific reports,
S Scala, and R Pacelli, and R V Iaffaioli, and N Normanno, and S Pepe, and G Frasci, and G Genua, and T Tsuruo, and P Tagliaferri, and A R Bianco
[Uptake and distribution of adriamycin in multidrug-resistant LoVo/Adr cells].
March 2002, Di 1 jun yi da xue xue bao = Academic journal of the first medical college of PLA,
S Scala, and R Pacelli, and R V Iaffaioli, and N Normanno, and S Pepe, and G Frasci, and G Genua, and T Tsuruo, and P Tagliaferri, and A R Bianco
Reversal by cefoperazone of resistance to etoposide, doxorubicin, and vinblastine in multidrug resistant human sarcoma cells.
December 1989, Cancer research,
S Scala, and R Pacelli, and R V Iaffaioli, and N Normanno, and S Pepe, and G Frasci, and G Genua, and T Tsuruo, and P Tagliaferri, and A R Bianco
Reversal of multidrug resistance by transduction of cytokine genes into human colon carcinoma cells.
October 1996, Journal of the National Cancer Institute,
S Scala, and R Pacelli, and R V Iaffaioli, and N Normanno, and S Pepe, and G Frasci, and G Genua, and T Tsuruo, and P Tagliaferri, and A R Bianco
Reversal of heavy metal resistance in multidrug-resistant human KB carcinoma cells.
July 1997, Biochemical and biophysical research communications,
Copied contents to your clipboard!